MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Rheumatoid Arthritis Research and Therapies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

4,001 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
4,001 works in the cohort · of 4,299,418page 1 of 81

Labels cover 11 of 4,001 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 4,001 of 4,001 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
Edward Keystone, Arthur F. Kavanaugh, John T. Sharp, H Tannenbaum, Hua Ye, Leah Teoh +2 more
2004· article· en· Arthritis & Rheumatism· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1,171
citations
affunlabeled
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
Paul Emery, Edward Keystone, Hans‐Peter Tony, Alain Cantagrel, Ronald van Vollenhoven, Antonio Sánchez +3 more
2008· article· en· Annals of the Rheumatic Diseases· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1,113
citations
affunlabeled
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor, Edward Keystone, Désirée van der Heijde, Michael E. Weinblatt, Liliana Morales, Jaime Reyes Gonzaga +10 more
2017· article· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
951
citations
affunlabeled
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
George A. Wells, J-C Becker, J. Teng, Maxime Dougados, Michael Schiff, Josef S Smolen +2 more
2008· article· en· Annals of the Rheumatic Diseases· Medicine
distilled prediction:candidate · noneconsensus · none
892
citations
affno abstractunlabeled
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
C. Roubille, Vincent Richer, Tara Starnino, Collette McCourt, Alexandra McFarlane, Patrick Fleming +10 more
2015· review· en· Annals of the Rheumatic Diseases· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
890
citations
affunlabeled
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study
Edward Keystone, Désirée van der Heijde, David Mason, Robert Landewé, Ronald van Vollenhoven, Bernard Combe +5 more
2008· article· en· Arthritis & Rheumatism· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · metaepi_narrow
577
citations
affunlabeled
EULAR definition of difficult-to-treat rheumatoid arthritis
György Nagy, Nadia M T Roodenrijs, Paco M J Welsing, Melinda Kedves, Attila Hamar, Marlies C. van der Goes +25 more
2020· article· en· Annals of the Rheumatic Diseases· Medicine
distilled prediction:candidate · noneconsensus · none
539
citations
affunlabeled
Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative
K. Visser, Wanruchada Katchamart, Estíbaliz Loza, Juan Antonio Martínez-López, Carine Salliot, Judith Trudeau +20 more
2008· article· en· Annals of the Rheumatic Diseases· Medicine
distilled prediction:candidate · metaresearchconsensus · none
491
citations
next →

How this was built: Screen · Findings · About